एटेनोलोल और क्लोरथैलिडोन के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें एटेनोलोल और क्लोरथैलिडोन (Tenoretic; बीटा ब्लॉकर) के 430 इंटरैक्शन दर्ज हैं: 42 गंभीर, 345 मध्यम, 40 मामूली, और 3 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (42)

  • आर्सेनिक ट्राइऑक्साइडQT अंतराल बढ़ाने वाली दवागंभीर

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (आर्सेनिक ट्राइऑक्साइड लेबल, चेतावनियां और सावधानियां)

  • इट्राकोनाज़ोलएज़ोल एंटीफंगलगंभीर

    Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • Avoid diuretics or laxatives in patients with diarrhea. (इरिनोटेकन लेबल, चेतावनियां और सावधानियां)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकगंभीर

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (एथाक्रिनिक एसिड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एनालाप्रिलैटACE इनहिबिटरगंभीर

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (एनालाप्रिलैट लेबल, चेतावनियां)

  • एप्टिफिबाटाइडएंटीप्लेटलेट दवागंभीर

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (एप्टिफिबाटाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एप्लेरेनोनएल्डोस्टेरोन एंटागोनिस्टगंभीर

    …• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (एप्लेरेनोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एमिलोराइडपोटैशियम-स्पेयरिंग डाइयूरेटिकगंभीर

    Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (एमिलोराइड लेबल, बॉक्स्ड चेतावनी)

  • एसिटाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (कोरियोगोनाडोट्रोपिन अल्फा लेबल, चेतावनियां)

  • क्लोज़ापिनएंटीसाइकोटिकगंभीर

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (क्लोज़ापिन लेबल, बॉक्स्ड चेतावनी)

  • क्विनाप्रिलACE इनहिबिटरगंभीर

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (क्विनाप्रिल लेबल, चेतावनियां)

  • जेंटामाइसिनएमिनोग्लाइकोसाइडगंभीर

    The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (जेंटामाइसिन लेबल, बॉक्स्ड चेतावनी)

  • ज़ोनिसामाइडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • टैडालाफिलPDE5 इनहिबिटरगंभीर

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

  • ट्रैनिलसाइप्रोमिनMAO इनहिबिटरगंभीर

    …Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

  • डाइक्लोरफेनामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (डायज़ॉक्साइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डोफेटिलाइडएंटीएरिदमिकगंभीर

    In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

  • डोरज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डोरज़ोलामाइड और टिमोलोलकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • ड्रोपेरिडोलडोपामिन एंटागोनिस्टगंभीर

    Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (ड्रोपेरिडोल लेबल, बॉक्स्ड चेतावनी)

  • नियोमाइसिनएमिनोग्लाइकोसाइडगंभीर

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (नियोमाइसिन लेबल, बॉक्स्ड चेतावनी)

  • नेबिवोलोलबीटा ब्लॉकरगंभीर

    Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (नेबिवोलोल लेबल, दवाओं के इंटरैक्शन)

  • पोटैशियम साइट्रेटपोटैशियम सप्लीमेंटगंभीर

    The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (पोटैशियम साइट्रेट लेबल, दवाओं के इंटरैक्शन)

  • Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (प्रोटामिन लेबल, बॉक्स्ड चेतावनी)

  • Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (फॉलिट्रोपिन लेबल, चेतावनियां और सावधानियां)

  • फ्लेकेनाइडएंटीएरिदमिकगंभीर

    Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (फ्लेकेनाइड लेबल, बॉक्स्ड चेतावनी)

  • बुमेटेनाइडलूप डाइयूरेटिकगंभीर

    WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (बुमेटेनाइड लेबल, बॉक्स्ड चेतावनी)

  • ब्रिंज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • मिनोक्सिडिलवैसोडाइलेटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (मेटाइरोसिन लेबल, चेतावनियां)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकगंभीर

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (मेटोलाज़ोन लेबल, चेतावनियां)

  • मेथाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • रिवास्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरगंभीर

    Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (रिवास्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

  • रेपाग्लिनाइडमेग्लिटिनाइडगंभीर

    Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

  • सल्फाडायज़िनसल्फोनामाइडगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सल्फासालाज़िनसल्फोनामाइडगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • साइक्लोस्पोरिनइम्यूनोसप्रेसेंटगंभीर

    Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (साइक्लोस्पोरिन लेबल, दवाओं के इंटरैक्शन)

  • सिल्वर सल्फाडायज़िनसल्फोनामाइडगंभीर

    CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (एटेनोलोल और क्लोरथैलिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (सोडियम बाइकार्बोनेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

मध्यम इंटरैक्शन (345)

  • अल्फुज़ोसिनअल्फा ब्लॉकरमध्यम

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (अल्फुज़ोसिन लेबल, चेतावनियां और सावधानियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

  • The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (आइवाब्राडिन लेबल, दवाओं के इंटरैक्शन)

  • आइसोप्रेनालिनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • आइसोफ्लुरेनजनरल एनेस्थेटिकमध्यम

    Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (आइसोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • आरफॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • आर्टिकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • आर्मोडाफिनिलCNS स्टिमुलेंटमध्यम

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (आर्मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

  • इंडापामाइडथायज़ाइड डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन एस्पार्टइंसुलिनमध्यम

    At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इंसुलिन ग्लार्जिनइंसुलिनमध्यम

    At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इंसुलिन डेग्लुडेकइंसुलिनमध्यम

    At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इंसुलिन डेटेमिरइंसुलिनमध्यम

    At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इंसुलिन लिस्प्रोइंसुलिनमध्यम

    At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इप्राट्रोपियमएंटीकोलिनर्जिकमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इप्राट्रोपियम और सैल्बुटामोलएंटीकोलिनर्जिकमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इब्यूटिलाइडएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • इमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (इमिप्रामिन लेबल, चेतावनियां)

  • इर्बेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • इलोपेरिडोनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

  • इसराडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एक्लिडिनियमएंटीकोलिनर्जिकमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एज़िलसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एटेनोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एटोडोलैकNSAIDमध्यम

    Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (एटोडोलैक लेबल, चेतावनियां)

  • एटोमोक्सेटिननॉरएपिनेफ्रिन रीअपटेक इनहिबिटरमध्यम

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

  • एडेनोसिनएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • एड्रेनालिनसिम्पैथोमिमेटिकमध्यम

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • एनालाप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

  • एपोप्रोस्टेनोलप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • एमिकासिनएमिनोग्लाइकोसाइडमध्यम

    Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (एमिकासिन लेबल, दवाओं के इंटरैक्शन)

  • एमिनोफाइलिनमिथाइलज़ैंथिनमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एमियोडेरोनएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • एम्पाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (एम्पाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

  • Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (एम्पाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, चेतावनियां और सावधानियां)

  • एम्लोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एम्लोडिपिन और एटोरवास्टेटिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एम्लोडिपिन और ओल्मेसार्टनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एम्लोडिपिन और बेनाज़ेप्रिलडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एम्लोडिपिन और वाल्सार्टनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एरिपिप्राज़ोलएंटीसाइकोटिकमध्यम

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

  • एर्गोटामिन और कैफीनएर्गोट एल्कलॉइडमध्यम

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (एर्गोटामिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

  • एलिस्किरेनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (एलोग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

  • एलोप्यूरिनॉलज़ैंथिन ऑक्सीडेज़ इनहिबिटरमध्यम

    Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

  • एल्प्रोस्टाडिलप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Beta-Blockers: e.g., metoprolol timolol ↑ beta-blockers Clinical monitoring is recommended and a dosage decrease of the beta blocker may be necessary when these agents are coadministered with GENVOYA. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

  • एवानाफिलPDE5 इनहिबिटरमध्यम

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (एवानाफिल लेबल, चेतावनियां और सावधानियां)

  • एसिब्यूटोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • एसेनापिनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (एसेनापिन लेबल, चेतावनियां और सावधानियां)

  • एसोमेप्राज़ोलप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (एसोमेप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • एस्पिरिनNSAIDमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • एस्पिरिन और डाइपिरिडामोलएंटीप्लेटलेट दवामध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • एस्मोलोलबीटा ब्लॉकरमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (एस्सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

  • Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (ऑक्ट्रियोटाइड लेबल, चेतावनियां और सावधानियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (ऑक्साप्रोज़िन लेबल, चेतावनियां और सावधानियां)

  • ऑक्सीकोडोनओपिओइडमध्यम

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीकोडोन लेबल, दवाओं के इंटरैक्शन)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सीमेटाज़ोलिनडीकंजेस्टेंटमध्यम

    Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (ऑक्सीमेटाज़ोलिन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सीमॉर्फोनओपिओइडमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • ओमेप्राज़ोलप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (ओमेप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • ओमेप्राज़ोल और सोडियम बाइकार्बोनेटप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (ओमेप्राज़ोल और सोडियम बाइकार्बोनेट लेबल, चेतावनियां और सावधानियां)

  • ओलिसेरिडिनओपिओइडमध्यम

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

  • ओलैंज़ापिनएंटीसाइकोटिकमध्यम

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (ओलैंज़ापिन लेबल, चेतावनियां और सावधानियां)

  • ओलैंज़ापिन और फ्लुओक्सेटिनएंटीसाइकोटिकमध्यम

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • ओल्मेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • कार्बामाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (कार्बामाज़ेपिन लेबल, चेतावनियां और सावधानियां)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

  • कार्बिडोपा और लेवोडोपाडोपामिनर्जिक दवामध्यम

    Antihypertensive drugs: May cause symptomatic postural hypotension. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

  • कार्बिडोपा, लेवोडोपा और एंटाकैपोनडोपामिनर्जिक दवामध्यम

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

  • कार्बोप्रोस्टप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • कार्वेडिलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • कीटोकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (कीटोप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • कीटोरोलैकNSAIDमध्यम

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (कीटोरोलैक लेबल, चेतावनियां और सावधानियां)

  • कैंडेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • कैनाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

  • कैप्टोप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • कैरिप्राज़िनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

  • Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (कैल्शियम क्लोराइड लेबल, दवाओं के इंटरैक्शन)

  • कैल्सिट्रिओलविटामिन D एनालॉगमध्यम

    Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (कैल्सिट्रिओल लेबल, दवाओं के इंटरैक्शन)

  • कोडीनओपिओइडमध्यम

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (कोडीन लेबल, दवाओं के इंटरैक्शन)

  • कोलेस्टिरामिनबाइल एसिड सीक्वेस्ट्रेंटमध्यम

    Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (कोलेस्टिरामिन लेबल, दवाओं के इंटरैक्शन)

  • क्लोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • क्लोफाराबिनएंटीमेटाबोलाइटमध्यम

    Consider use of diuretics and/or albumin. (क्लोफाराबिन लेबल, चेतावनियां और सावधानियां)

  • क्लोरथैलिडोनथायज़ाइड डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • क्लोरप्रोमाज़िनएंटीसाइकोटिकमध्यम

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (क्लोरप्रोमाज़िन लेबल, सावधानियां)

  • क्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • क्विनिडिनएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • क्वेटियापिनएंटीसाइकोटिकमध्यम

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

  • ग्लिपिज़ाइडसल्फोनिलयूरियामध्यम

    …may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic… (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

  • ग्लिपिज़ाइड और मेटफॉर्मिनसल्फोनिलयूरियामध्यम

    Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (ग्लिपिज़ाइड और मेटफॉर्मिन लेबल, सावधानियां)

  • ग्लिबेनक्लामाइडसल्फोनिलयूरियामध्यम

    …Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (ग्लिबेनक्लामाइड लेबल, दवाओं के इंटरैक्शन)

  • ग्लिमेपिराइडसल्फोनिलयूरियामध्यम

    …glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol,… (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

  • Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (ग्लूकागॉन लेबल, दवाओं के इंटरैक्शन)

  • ग्वानफेसिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ज़ाइल्यूटॉनCYP1A2 इनहिबिटरमध्यम

    Zileuton increases propranolol levels and beta-blocker activity. (ज़ाइल्यूटॉन लेबल, दवाओं के इंटरैक्शन)

  • ज़िप्रासिडोनएंटीसाइकोटिकमध्यम

    Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

  • ज़ोलेड्रोनिक एसिडबिस्फॉस्फोनेटमध्यम

    Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (ज़ोलेड्रोनिक एसिड लेबल, चेतावनियां और सावधानियां)

  • टरब्यूटालिनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टिज़ानिडिनमसल रिलैक्सेंटमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टियोट्रोपियमएंटीकोलिनर्जिकमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टिर्ज़ेपाटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टेट्राबेनाज़िनVMAT2 इनहिबिटरमध्यम

    Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • टेपेंटाडोलओपिओइडमध्यम

    …use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (टेपेंटाडोल लेबल, दवाओं के इंटरैक्शन)

  • टेराज़ोसिनअल्फा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टेरिपैराटाइडथायरॉइड हार्मोनमध्यम

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टेल्मिसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टेल्मिसार्टन और एम्लोडिपिनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टेस्टोस्टेरोनएंड्रोजनमध्यम

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

  • टैक्रोलिमसइम्यूनोसप्रेसेंटमध्यम

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (टैक्रोलिमस लेबल, चेतावनियां और सावधानियां)

  • टैम्सुलोसिनअल्फा ब्लॉकरमध्यम

    Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

  • टॉरसेमाइडलूप डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • टोब्रामाइसिनएमिनोग्लाइकोसाइडमध्यम

    Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (टोब्रामाइसिन लेबल, दवाओं के इंटरैक्शन)

  • टोरेमिफेनसेलेक्टिव एस्ट्रोजन रिसेप्टर मॉड्यूलेटरमध्यम

    Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

  • टोल्मेटिनNSAIDमध्यम

    Use of tolmetin may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see PRECAUTIONS: Drug Interactions ). (टोल्मेटिन लेबल, चेतावनियां)

  • Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (टोल्वैप्टन लेबल, चेतावनियां और सावधानियां)

  • ट्राइफ्लुओपेराज़िनएंटीसाइकोटिकमध्यम

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (ट्राइफ्लुओपेराज़िन लेबल, सावधानियां)

  • ट्रामाडोलओपिओइडमध्यम

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ट्रामाडोल लेबल, दवाओं के इंटरैक्शन)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ट्रामाडोल और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमटेरिनपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ट्रेप्रोस्टिनिलप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • ट्रैंडोलाप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ट्रैज़ोडोनएंटीडिप्रेसेंटमध्यम

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

  • डाइएथिलप्रोपियॉनCNS स्टिमुलेंटमध्यम

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (डाइएथिलप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (डाइक्लोफेनाक लेबल, चेतावनियां और सावधानियां)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • डाइनोप्रोस्टोनप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume depleted, and the elderly. (डाइफ्लुनिसाल लेबल, चेतावनियां)

  • डाइसोपाइरामाइडएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • डाइहाइड्रोएर्गोटामिनएर्गोट एल्कलॉइडमध्यम

    Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (डाइहाइड्रोएर्गोटामिन लेबल, दवाओं के इंटरैक्शन)

  • डारुनाविरएंटीरेट्रोवायरलमध्यम

    …initial dosing and titration of quetiapine. e.g. perphenazine, risperidone, thioridazine ↑ antipsychotics A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with PREZISTA/ritonavir. β-Blockers : e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring of patients is recommended. (डारुनाविर लेबल, दवाओं के इंटरैक्शन)

  • डारुनाविर और कोबिसिस्टैटएंटीरेट्रोवायरलमध्यम

    Initiation of quetiapine in patients taking PREZCOBIX or PREZCOBIX PED : Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. β-Blockers: e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6. (डारुनाविर और कोबिसिस्टैट लेबल, दवाओं के इंटरैक्शन)

  • डिगॉक्सिनडिजिटेलिस ग्लाइकोसाइडमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • डिल्टियाज़ेमकैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (डुलोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • डेक्समिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    • Antihypertensive Drugs: Monitor blood pressure. (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

  • डेक्सलैंसोप्राज़ोलप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (डेक्सलैंसोप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (डेसवेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

  • डेसिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (डेसिप्रामिन लेबल, चेतावनियां)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

  • डैपाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (डैपाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

  • Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (डैपाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, चेतावनियां और सावधानियां)

  • डॉक्सरकैल्सिफेरॉलविटामिन D एनालॉगमध्यम

    Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (डॉक्सरकैल्सिफेरॉल लेबल, चेतावनियां और सावधानियां)

  • डॉक्साज़ोसिनअल्फा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ड्यूटास्टेराइड और टैम्सुलोसिन5-अल्फा रिडक्टेज़ इनहिबिटरमध्यम

    Nifedipine, Atenolol, Enalapril Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with nifedipine, atenolol, or enalapril [see Clinical Pharmacology (12.3) ]. (ड्यूटास्टेराइड और टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

  • ड्यूटेट्राबेनाज़िनVMAT2 इनहिबिटरमध्यम

    Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • ड्रोनेडेरोनएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां और सावधानियां)

  • थियोफाइलिनमिथाइलज़ैंथिनमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • नाइट्रोग्लिसरीननाइट्रेटमध्यम

    Antihypertensives: Possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

  • नाइट्रोप्रुसाइडवैसोडाइलेटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • नाडोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • नालबुफिनओपिओइडमध्यम

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (नालबुफिन लेबल, दवाओं के इंटरैक्शन)

  • नाल्ट्रेक्सोन और ब्यूप्रोपियॉनओपिओइड एंटागोनिस्टमध्यम

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

  • निकार्डिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • निफेडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • निमोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • नियासिनमध्यम

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (नियासिन लेबल, दवाओं के इंटरैक्शन)

  • निसोल्डिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • नेटेग्लिनाइडमेग्लिटिनाइडमध्यम

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy (nerve disease), in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)] , or in patients who experience recurrent hypoglycemia. (नेटेग्लिनाइड लेबल, चेतावनियां और सावधानियां)

  • ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (नेप्रोक्सेन लेबल, चेतावनियां और सावधानियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • नैबुमेटोनNSAIDमध्यम

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (नैबुमेटोन लेबल, चेतावनियां)

  • पाइरिडोस्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमध्यम

    Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (पाइरिडोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (पाइरोक्सिकैम लेबल, चेतावनियां और सावधानियां)

  • पाइलोकार्पिनकोलिनर्जिक एगोनिस्टमध्यम

    Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (पाइलोकार्पिन लेबल, दवाओं के इंटरैक्शन)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

  • पिंडोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • पियोग्लिटाज़ोन और ग्लिमेपिराइडथायज़ोलिडिनडायोनमध्यम

    …glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol,… (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (पेंटाज़ोसिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

  • पेंटोक्सिफाइलिनमिथाइलज़ैंथिनमध्यम

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • पेथिडीनओपिओइडमध्यम

    Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (पेथिडीन लेबल, दवाओं के इंटरैक्शन)

  • पेरिंडोप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • पैंटोप्राज़ोलप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (पैंटोप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (पैरासिटामोल और आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (पैरासिटामोल और कोडीन लेबल, दवाओं के इंटरैक्शन)

  • पैरिकैल्सिटोलविटामिन D एनालॉगमध्यम

    The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (पैरिकैल्सिटोल लेबल, चेतावनियां और सावधानियां)

  • Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (पैरोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • पैलिपेरिडोनएंटीसाइकोटिकमध्यम

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (पैसिरियोटाइड लेबल, चेतावनियां और सावधानियां)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (पोटैशियम आयोडाइड लेबल, दवाओं के इंटरैक्शन)

  • पोनेसिमोडइम्यूनोसप्रेसेंटमध्यम

    Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (पोनेसिमोड लेबल, चेतावनियां और सावधानियां)

  • प्राज़ोसिनअल्फा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • प्रिलोकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • प्रोकेनामाइडएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • प्रोक्लोरपेराज़िनएंटीसाइकोटिकमध्यम

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (प्रोक्लोरपेराज़िन लेबल, सावधानियां)

  • प्रोपाइलथायोयूरेसिलएंटीथायरॉइड दवामध्यम

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • प्रोपाफेनोनएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • प्रोप्रानोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Diuretics : Codeine may reduce the efficacy of diuretics. (प्रोमेथाज़िन और कोडीन लेबल, दवाओं के इंटरैक्शन)

  • फेंटरमिन और टोपिरामेटCNS स्टिमुलेंटमध्यम

    In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting. (फेंटरमिन और टोपिरामेट लेबल, चेतावनियां और सावधानियां)

  • फेंटानिलओपिओइडमध्यम

    …treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (फेंटानिल लेबल, चेतावनियां और सावधानियां)

  • फेनेलज़िनMAO इनहिबिटरमध्यम

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (फेनेलज़िन लेबल, चेतावनियां)

  • फेनोक्सीबेंज़ामिनअल्फा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (फेनोप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • फेलोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • फॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • फॉस्कारनेटएंटीवायरलमध्यम

    When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

  • फोसिनोप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (फ्लर्बिप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • फ्लुकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (फ्लुकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • फ्लुटिकासोन और सैल्मेटेरोलकॉर्टिकोस्टेरॉइडमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • फ्लुड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमध्यम

    Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (फ्लुड्रोकॉर्टिसोन लेबल, दवाओं के इंटरैक्शन)

  • Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

  • बिमाटोप्रोस्टप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • बिसोप्रोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • बीटाक्सोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • बुडेसोनाइड और फॉर्मोटेरोलकॉर्टिकोस्टेरॉइडमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • बेंज़फेटामाइनCNS स्टिमुलेंटमध्यम

    Amphetamines may decrease the hypotensive effect of antihypertensives. (बेंज़फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • बेक्साग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (बेक्साग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

  • बेनाज़ेप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • बेलाडोना और ओपियमओपिओइडमध्यम

    Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (बेलाडोना और ओपियम लेबल, दवाओं के इंटरैक्शन)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूपिवाकेनलोकल एनेस्थेटिकमध्यम

    Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

  • ब्यूपिवाकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूप्रेनॉर्फिनओपिओइडमध्यम

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

  • Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूप्रोपियॉनएंटीडिप्रेसेंटमध्यम

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (ब्यूप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

  • ब्रिमोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

  • ब्रिमोनिडिन और टिमोलोलअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

  • ब्रेक्सपिप्राज़ोलएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (ब्रोमफेनिरामिन, स्यूडोएफेड्रिन और डेक्सट्रोमेथॉर्फन लेबल, दवाओं के इंटरैक्शन)

  • ब्रोमोक्रिप्टिनडोपामिन एगोनिस्टमध्यम

    Use caution in patients taking antihypertensive medications. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

  • मिथाइलएर्गोमेट्रिनएर्गोट एल्कलॉइडमध्यम

    Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (मिथाइलएर्गोमेट्रिन लेबल, दवाओं के इंटरैक्शन)

  • मिथाइलडोपाएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • मिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    Antihypertensive Drugs: Monitor blood pressure. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

  • मिराबेग्रॉनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • मिर्टाज़ापिनएंटीडिप्रेसेंटमध्यम

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (मिर्टाज़ापिन लेबल, चेतावनियां और सावधानियां)

  • Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

  • मिसोप्रोस्टोलप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • मेकामाइलामिनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • मेक्सिलेटिनएंटीएरिदमिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • मेटोप्रोलोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • मेथाडोनओपिओइडमध्यम

    Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (मेथाडोन लेबल, चेतावनियां और सावधानियां)

  • मेथिमाज़ोलएंटीथायरॉइड दवामध्यम

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (मेफेनामिक एसिड लेबल, चेतावनियां और सावधानियां)

  • मेफ्लोक्वीनमलेरिया-रोधी दवामध्यम

    There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (मेलोक्सिकैम लेबल, चेतावनियां और सावधानियां)

  • मॉर्फिनओपिओइडमध्यम

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (मॉर्फिन लेबल, दवाओं के इंटरैक्शन)

  • मोएक्सिप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (मोटिक्साफोर्टाइड लेबल, चेतावनियां और सावधानियां)

  • मोडाफिनिलCNS स्टिमुलेंटमध्यम

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

  • यूमेक्लिडिनियमएंटीकोलिनर्जिकमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • यूमेक्लिडिनियम और विलैंटेरोलएंटीकोलिनर्जिकमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • रिटोनाविरएंटीरेट्रोवायरलमध्यम

    The impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (रिटोनाविर लेबल, चेतावनियां और सावधानियां)

  • रिफापेंटिनएंटीबायोटिकमध्यम

    …Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

  • रिफैम्पिसिनएंटीबायोटिकमध्यम

    Decrease exposure Beta-blockers Metoprolol Decrease exposure Propranolol Decrease exposure Benzodiazepines Diazepam , Administered with rifampin 1200 mg daily Decrease exposure Benzodiazepine-related drugs Zopiclone Decrease AUC by 82% Zolpidem Decrease AUC by 73% Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as… (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

  • रियोसिगुआटवैसोडाइलेटरमध्यम

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (रियोसिगुआट लेबल, चेतावनियां और सावधानियां)

  • रिस्पेरिडोनएंटीसाइकोटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • रैबेप्राज़ोलप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (रैबेप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • रैमिप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • रोपिवाकेनलोकल एनेस्थेटिकमध्यम

    Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (रोपिवाकेन लेबल, चेतावनियां और सावधानियां)

  • लिडोकेनलोकल एनेस्थेटिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • लिडोकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • लिडोकेन और प्रिलोकेनलोकल एनेस्थेटिकमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • लिथियमसेरोटोनर्जिक दवामध्यम

    Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • लिनेज़ोलिडएंटीबायोटिकमध्यम

    Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

  • लियोथायरोनिनथायरॉइड हार्मोनमध्यम

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लिसिनोप्रिलACE इनहिबिटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लुमाटेपेरोनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

  • Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (लेडिपासविर और सोफोसबुविर लेबल, चेतावनियां और सावधानियां)

  • लेबेटालोलबीटा ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लेवॉर्फेनॉलओपिओइडमध्यम

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (लेवॉर्फेनॉल लेबल, दवाओं के इंटरैक्शन)

  • लेवोथायरोक्सिनथायरॉइड हार्मोनमध्यम

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लेवोथायरोक्सिन और लियोथायरोनिनथायरॉइड हार्मोनमध्यम

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (लेवोमिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

  • लेवोसैल्बुटामोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लैंसोप्राज़ोलप्रोटॉन पंप इनहिबिटरमध्यम

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (लैंसोप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • लैकोसामाइडएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (लैकोसामाइड लेबल, चेतावनियां और सावधानियां)

  • लैटानोप्रोस्टप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (लैनरियोटाइड लेबल, दवाओं के इंटरैक्शन)

  • लोपिनाविर और रिटोनाविरएंटीरेट्रोवायरलमध्यम

    The impact on the PR interval of co-administration of KALETRA with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (लोपिनाविर और रिटोनाविर लेबल, चेतावनियां और सावधानियां)

  • लोफेक्सिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लोसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • लोसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • ल्यूरासिडोनएंटीसाइकोटिकमध्यम

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

  • वार्डेनाफिलPDE5 इनहिबिटरमध्यम

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (वार्डेनाफिल लेबल, दवाओं के इंटरैक्शन)

  • वाल्बेनाज़िनVMAT2 इनहिबिटरमध्यम

    Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • वाल्सार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • विटामिन Dविटामिन और मिनरलमध्यम

    थायज़ाइड डाइयूरेटिक कैल्शियम का उत्सर्जन कम करते हैं; विटामिन D और कैल्शियम सप्लीमेंट के साथ मिलकर इससे हाइपरकैल्सीमिया हो सकता है, खासकर बुज़ुर्गों में। (NIH Office of Dietary Supplements, Vitamin D)

  • विबेग्रॉनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (विलाज़ोडोन लेबल, चेतावनियां और सावधानियां)

  • Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

  • वेरापामिलकैल्शियम चैनल ब्लॉकरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • वोर्टियोक्सेटिनएंटीडिप्रेसेंटमध्यम

    Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (वोर्टियोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • सक्सिनिलकोलिनन्यूरोमस्कुलर ब्लॉकरमध्यम

    Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (सक्सिनिलकोलिन लेबल, चेतावनियां और सावधानियां)

  • Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (सर्ट्रालिन लेबल, चेतावनियां और सावधानियां)

  • साइक्लोफॉस्फामाइडइम्यूनोसप्रेसेंटमध्यम

    …inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity… (साइक्लोफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोबेंज़ाप्रिनमसल रिलैक्सेंटमध्यम

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

  • साल्सालेटNSAIDमध्यम

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (साल्सालेट लेबल, चेतावनियां)

  • Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

  • सिलोडोसिनअल्फा ब्लॉकरमध्यम

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (सिलोडोसिन लेबल, चेतावनियां और सावधानियां)

  • सिल्डेनाफिलPDE5 इनहिबिटरमध्यम

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (सिल्डेनाफिल लेबल, चेतावनियां और सावधानियां)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (सुमाट्रिप्टान और नेप्रोक्सेन लेबल, चेतावनियां और सावधानियां)

  • सुलिंडैकNSAIDमध्यम

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume-depleted, and the elderly. (सुलिंडैक लेबल, चेतावनियां)

  • सेफेपिमसेफालोस्पोरिनमध्यम

    Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (सेफेपिम लेबल, दवाओं के इंटरैक्शन)

  • सेफ्टाज़िडिमसेफालोस्पोरिनमध्यम

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (सेफ्टाज़िडिम लेबल, दवाओं के इंटरैक्शन)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia , heart failure, liver dysfunction, those taking diuretics, ACE inhibitors or the ARBs, and the elderly. (सेलेकॉक्सिब लेबल, चेतावनियां और सावधानियां)

  • सेविमेलिनकोलिनर्जिक एगोनिस्टमध्यम

    DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (सेविमेलिन लेबल, दवाओं के इंटरैक्शन)

  • सैक्यूबिट्रिल और वाल्सार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • सैल्बुटामोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • सैल्मेटेरोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • सोटालोलबीटा ब्लॉकरमध्यम

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (एटेनोलोल और क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

  • Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (सोडियम ज़िरकोनियम साइक्लोसिलिकेट लेबल, चेतावनियां और सावधानियां)

  • Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (सोफोसबुविर और वेल्पाटासविर लेबल, चेतावनियां और सावधानियां)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

  • स्पिरोनोलैक्टोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइडएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • हाइड्रालाज़िनवैसोडाइलेटरमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • हाइड्रोकोडोनओपिओइडमध्यम

    Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन लेबल, दवाओं के इंटरैक्शन)

  • Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs (see PRECAUTIONS: Drug Interactions). (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, चेतावनियां)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, दवाओं के इंटरैक्शन)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रोक्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

  • हाइड्रोमॉर्फोनओपिओइडमध्यम

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (हाइड्रोमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • हेलोपेरिडोलएंटीसाइकोटिकमध्यम

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (हेलोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

मामूली ज़िक्र (40)

  • इकाटिबेंटमामूली

    ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (इकाटिबेंट लेबल, दवाओं के इंटरैक्शन)

  • इमैटिनिबCYP3A4 इनहिबिटरमामूली

    Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (इमैटिनिब लेबल, चेतावनियां और सावधानियां)

  • एकार्बोज़एंटीडायबिटिक (डायबिटीज़ की दवा)मामूली

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (एकार्बोज़ लेबल, दवाओं के इंटरैक्शन)

  • एफेड्रिनसिम्पैथोमिमेटिकमामूली

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (एफेड्रिन लेबल, दवाओं के इंटरैक्शन)

  • Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (एम्ब्रिसेंटन लेबल, चेतावनियां और सावधानियां)

  • In addition to discontinuation of the drug, diuretic therapy may be required. (एस्टरीफाइड एस्ट्रोजन और मिथाइलटेस्टोस्टेरोन लेबल, चेतावनियां)

  • कैल्शियमविटामिन और मिनरलमामूली

    थायज़ाइड डाइयूरेटिक कैल्शियम का उत्सर्जन कम करते हैं, इसलिए कैल्शियम का अधिक सेवन खून में कैल्शियम बढ़ा सकता है। (NIH Office of Dietary Supplements, Calcium)

  • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (कैल्शियम ग्लूकोनेट लेबल, दवाओं के इंटरैक्शन)

  • Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (कॉर्टिकोट्रोपिन लेबल, दवाओं के इंटरैक्शन)

  • कोलेस्टिपोलबाइल एसिड सीक्वेस्ट्रेंटमामूली

    Effects on the absorption of other beta-blockers have not been determined. (कोलेस्टिपोल लेबल, दवाओं के इंटरैक्शन)

  • ग्लिबेनक्लामाइड और मेटफॉर्मिनसल्फोनिलयूरियामामूली

    Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (ग्लिबेनक्लामाइड और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

  • ज़िंकविटामिन और मिनरलमामूली

    थायज़ाइड डाइयूरेटिक लंबे समय तक इस्तेमाल करने पर पेशाब में ज़िंक की हानि बढ़ाते हैं। (NIH Office of Dietary Supplements, Zinc)

  • टर्बिनाफिनएंटीफंगलमामूली

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमसिनोलोनकॉर्टिकोस्टेरॉइडमामूली

    Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (ट्रायमसिनोलोन लेबल, दवाओं के इंटरैक्शन)

  • डासाटिनिबमामूली

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (डासाटिनिब लेबल, चेतावनियां और सावधानियां)

  • डेक्सट्रोएम्फेटामाइनCNS स्टिमुलेंटमामूली

    Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां)

  • Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

  • नॉरट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    The antihypertensive action of guanethidine and similar agents may be blocked. (नॉरट्रिप्टिलीन लेबल, चेतावनियां)

  • परफेनाज़िनएंटीसाइकोटिकमामूली

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (परफेनाज़िन लेबल, दवाओं के इंटरैक्शन)

  • पाइपेरासिलिन और टैज़ोबैक्टमपेनिसिलिन एंटीबायोटिकमामूली

    Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (पाइपेरासिलिन और टैज़ोबैक्टम लेबल, चेतावनियां और सावधानियां)

  • पियोग्लिटाज़ोन और मेटफॉर्मिनथायज़ोलिडिनडायोनमामूली

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (पियोग्लिटाज़ोन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

  • पेनिसिलिन Gपेनिसिलिन एंटीबायोटिकमामूली

    These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (पेनिसिलिन G लेबल, दवाओं के इंटरैक्शन)

  • पोटैशियमविटामिन और मिनरलमामूली

    लूप और थायज़ाइड डाइयूरेटिक पोटैशियम की हानि बढ़ाते हैं; कभी-कभी इनके साथ पोटैशियम सप्लीमेंट भी लिखा जाता है। (NIH Office of Dietary Supplements, Potassium)

  • प्रेडनिसोनकॉर्टिकोस्टेरॉइडमामूली

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोन लेबल, दवाओं के इंटरैक्शन)

  • प्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमामूली

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • प्रोट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (प्रोट्रिप्टिलीन लेबल, चेतावनियां)

  • फिंगोलिमोडइम्यूनोसप्रेसेंटमामूली

    Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (फिंगोलिमोड लेबल, दवाओं के इंटरैक्शन)

  • फिनास्टेराइड5-अल्फा रिडक्टेज़ इनहिबिटरमामूली

    …PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (फिनास्टेराइड लेबल, दवाओं के इंटरैक्शन)

  • बोसेंटनCYP3A4 इंड्यूसरमामूली

    Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (बोसेंटन लेबल, चेतावनियां और सावधानियां)

  • ब्यूटॉर्फेनॉलओपिओइडमामूली

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (ब्यूटॉर्फेनॉल लेबल, चेतावनियां)

  • मिथाइलटेस्टोस्टेरोनएंड्रोजनमामूली

    In addition to discontinuation of the drug, diuretic therapy may be required. (मिथाइलटेस्टोस्टेरोन लेबल, चेतावनियां)

  • मिथाइलप्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमामूली

    Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (मिथाइलप्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

  • मिलरिनोनPDE3 इनहिबिटरमामूली

    …been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (मिलरिनोन लेबल, दवाओं के इंटरैक्शन)

  • मेटफॉर्मिनबाइगुआनाइडमामूली

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

  • मैग्नीशियमविटामिन और मिनरलमामूली

    लूप और थायज़ाइड डाइयूरेटिक के लंबे समय तक इस्तेमाल से पेशाब में मैग्नीशियम की हानि बढ़ती है। (NIH Office of Dietary Supplements, Magnesium)

  • मैसिटेंटनमामूली

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (मैसिटेंटन लेबल, चेतावनियां और सावधानियां)

  • These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

  • Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (सिटाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

  • These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (सैक्साग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

कोई महत्वपूर्ण इंटरैक्शन नहीं बताया गया (3)

  • एटाज़ानाविरएंटीरेट्रोवायरलकोई इंटरैक्शन नहीं

    Drugs with No Observed Interactions with REYATAZ No clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, atenolol, or the nucleoside reverse transcriptase inhibitors lamivudine or zidovudine [see Clinical Pharmacology, Tables 21 and 22 (12.3) ] . (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

  • पैमिड्रोनेटबिस्फॉस्फोनेटकोई इंटरैक्शन नहीं

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (पैमिड्रोनेट लेबल, दवाओं के इंटरैक्शन)

  • रोपिनिरोलडोपामिन एगोनिस्टकोई इंटरैक्शन नहीं

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)

आप जो कुछ भी लेते हैं, उस सबके साथ एटेनोलोल और क्लोरथैलिडोन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।